No Increased Risk for Contrast-Induced Nephropathy after Multiple CT Perfusion Studies of the Brain with a Nonionic, Dimeric, Iso-Osmolal Contrast Medium

References

1. ↵
   Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930–36

   CrossRefPubMedWeb of Science
2. ↵
   Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542–48

   CrossRefPubMedWeb of Science
3. ↵
   Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002;90:1068–73

   CrossRefPubMedWeb of Science
4. ↵
   Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006;354:379–86

   CrossRefPubMedWeb of Science
5. ↵
   Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999;9:1602–13

   CrossRefPubMedWeb of Science
6. ↵
   McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003;4 Suppl 5:S3–9
7. ↵
   Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol 2003;181:1463–71

   CrossRefPubMedWeb of Science
8. ↵
   Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177–82

   FREE Full Text
9. ↵
   Heinrich M, Uder M. [Hydration for the prevention of contrast medium-induced nephropathy: an update]. Rofo 2006;178:378–84

   PubMed
10. ↵
    Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 2004;183:1673–89

    CrossRefPubMedWeb of Science
11. ↵
    McCullough PA. Renal safety of iodixanol. Expert Rev Cardiovasc Ther 2006;4:655–61

    CrossRefPubMed
12. ↵
    Dawson P, Howell M. The non-ionic dimers: a new class of contrast agents. Br J Radiol 1986;59:987–91

    Abstract/FREE Full Text
13. ↵
    Katzberg RW, Barrett BJ. Risk of iodinated contrast material–induced nephropathy with intravenous administration. Radiology 2007;243:622–28

    CrossRefPubMedWeb of Science
14. ↵
    Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491–99

    CrossRefPubMedWeb of Science
15. ↵
    Manual on Contrast Media, Version 5. Philadelphia: American College of Radiology;2007
16. ↵
    Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114–18

    CrossRefPubMedWeb of Science
17. Boccalandro F, Amhad M, Smalling RW, et al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003;58:336–41

    CrossRefPubMedWeb of Science
18. Briguori C, Colombo A, Airoldi F, et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 2005;68:2250–55

    CrossRefPubMedWeb of Science
19. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004;25:206–11

    Abstract/FREE Full Text
20. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202–07

    CrossRefPubMedWeb of Science
21. ↵
    Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 2004;25:212–18

    Abstract/FREE Full Text
22. ↵
    McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006;48:692–99

    CrossRefPubMedWeb of Science
23. ↵
    Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006;41:815–21

    CrossRefPubMedWeb of Science
24. ↵
    Carraro M, Malalan F, Antonione R, et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol 1998;8:144–47

    CrossRefPubMedWeb of Science
25. ↵
    Kolehmainen H, Soiva M. Comparison of Xenetic 300 and Visipaque 320 in patients with renal failure. Eur Radiol 1998;13:B32–33
26. ↵
    Petrik M, Weigel C, Kirsch M, et al. [No detectable nephrotoxic side effect using a dimer, non-ionic contrast media in cerebral perfusion computed tomography in case of suspected brain ischemia]. Rofo 2005;177:1242–49

    PubMed
27. ↵
    Thomsen HS, Morcos SK. Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines. Eur Radiol 2006;16:1835–40

    CrossRefPubMedWeb of Science
28. ↵
    Uder M, Heinrich M, Jansen A, et al. cAMP and cGMP do not mediate the vasorelaxation induced by iodinated radiographic contrast media in isolated swine renal arteries. Acta Radiol 2002;43:104–10

    FREE Full Text
29. ↵
    Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 2006;239:392–97

    CrossRefPubMedWeb of Science
30. ↵
    Alamartine E, Phayphet M, Thibaudin D, et al. Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations. Eur J Intern Med 2003;14:426–31

    CrossRefPubMed
31. Najjar M, Hamad A, Salameh M, et al. The risk of radiocontrast nephropathy in patients with cirrhosis. Ren Fail 2002;24:11–18

    CrossRefPubMed
32. ↵
    Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180–84

    CrossRefPubMedWeb of Science
33. ↵
    Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143–49

    CrossRefPubMedWeb of Science
34. Katzberg RW, Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Suppl 2006;100:S3–7

    PubMed
35. ↵
    Katzberg RW. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology 1997;204:297–312

    PubMedWeb of Science
36. ↵
    Liss P, Persson PB, Hansell P, et al. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int 2006;70:1811–17

    CrossRefPubMedWeb of Science
37. ↵
    Becker CR, Reiser MF. Use of iso-osmolar nonionic dimeric contrast media in multidetector row computed tomography angiography for patients with renal impairment. Invest Radiol 2005;40:672–75

    CrossRefPubMedWeb of Science
38. ↵
    Cramer BC, Parfrey PS, Hutchinson TA, et al. Renal function following infusion of radiologic contrast material. A prospective controlled study. Arch Intern Med 1985;145:87–89

    CrossRefPubMedWeb of Science
39. ↵
    Heller CA, Knapp J, Halliday J, et al. Failure to demonstrate contrast nephrotoxicity. Med J Aust 1991;155:329–32

    PubMed
40. ↵
    Shusterman N, Strom BL, Murray TG, et al. Risk factors and outcome of hospital-acquired acute renal failure. Clinical epidemiologic study. Am J Med 1987;83:65–71

    PubMedWeb of Science